Classification of uterine corpus carcinomas,
carcinosarcomas and sarcomas
Focus on molecular approaches
Prof. Ben Davidson, MD PhD
Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Issues
• Evolution
• Diagnosis
• Prognosis
• Therapy
Endometrial carcinoma
Matias-Guiu and Davidson, Virchows Arch 2014;464:315-331
Molecular pathways
Matias-Guiu and Davidson, Virchows Arch 2014;464:315-331
Prognosis
Uterine carcinosarcoma
Uterine sarcoma
• ESS cytogenetics: JAZF1-SUZ12 (JJAZ1)
JAZF1-PHF1
EPC1-PHF1
MEAF6-PHF1
ZC3H7B-BCOR
MBTD1-CXorf67
HG ESS: YWHAE-NUTM2A/B (FAM22A/B)
Summary
• The evolution of several uterine cancers is unclear
• Diagnosis is based on combination of morphology, IHC and
(in some situations) molecular findings
• There are distinct sub-groups with prognostic relevance
within established histological entities, most evidently in EEC
• The potential of targeted therapy is yet to be realized in
uterine cancer
Thank you for your attention